Senhwa Biosciences Inc (6492) AI Stock Analysis

Senhwa Biosciences Inc

(TPEx:6492)

Select Model

Rating:48Neutral

Price Target:TWD 29.00▼(-3.65% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is mainly impacted by moderate financial performance, where a robust balance sheet is offset by substantial R&D losses and cash burn. Weak technical indicators showing downward momentum add pressure, while valuation remains neutral given the sector's typical loss-making profile.

Positive Factors

Low LeverageDebt-to-equity has stayed modest at about 0.7%–2.9%, reaching roughly 2.9% in 2025. This low leverage limits interest and refinancing pressure relative to heavily indebted peers, preserving flexibility to fund research or manage volatility while the pipeline develops.

Negative Factors

Minimal and Declining RevenueRevenue remains extremely small and declined about 92.6% in 2025, showing that the company has not yet established meaningful commercial traction. Such a limited and shrinking revenue base leaves the business highly dependent on future pipeline progress, partnerships, or external funding.

Senhwa Biosciences Inc (6492) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 3.41B
Dividend Yield: ―
Average Volume (3M): 232.03K
Price to Earnings (P/E): -9.1
Beta (1Y): 0.53
Revenue Growth: 5.00%
EPS Growth: -6.49%
Country: TW
Employees: 15
Sector: General
Sector Strength: 55
Industry: Biotechnology

Senhwa Biosciences Inc Business Overview & Revenue Model

Company Description

Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its...

Senhwa Biosciences Inc Financial Statement Overview

Summary

Despite low income statement and cash flow scores due to R&D-driven losses and minimal revenue, the high balance sheet score reflects low debt and sufficient equity providing financial stability.

Income Statement

22Negative

Balance Sheet

85Very Positive

Cash Flow

28Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.05M	1.07M	1.00M	1.00M	1.00M	550.00K
Gross Profit	443.00K	520.00K	477.00K	552.00K	-6.61M	-5.91M
EBITDA	-302.91M	-266.15M	-279.71M	-283.79M	-340.60M	-321.59M
Net Income	-296.60M	-264.77M	-293.75M	-296.31M	-349.63M	-329.26M
Balance Sheet
Total Assets	679.25M	819.26M	1.07B	1.36B	1.65B	2.06B
Cash, Cash Equivalents and Short-Term Investments	636.92M	771.78M	1.03B	1.32B	1.62B	2.03B
Total Debt	17.92M	22.12M	14.99M	9.60M	16.16M	15.38M
Total Liabilities	62.61M	58.30M	38.92M	46.17M	40.93M	92.44M
Stockholders Equity	616.64M	760.96M	1.03B	1.32B	1.61B	1.97B
Cash Flow
Free Cash Flow	-257.22M	-248.74M	-296.17M	-291.13M	-400.34M	-300.45M
Operating Cash Flow	-256.71M	-248.46M	-294.22M	-286.35M	-399.97M	-300.05M
Investing Cash Flow	4.63M	5.82M	6.71M	-5.26M	-590.00K	149.00K
Financing Cash Flow	-9.60M	-9.34M	-8.72M	-8.83M	-19.55M	-34.24M

Senhwa Biosciences Inc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6492 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:1786	64Neutral	TWD 3.89B	26.80	―	3.67%	-2.25%	-15.57%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6492	48Neutral	TWD 3.44B	-9.10	―	―	5.00%	-6.49%
TW:6875	37Underperform	TWD 3.24B	-9.23	―	―	-69.26%	-24.53%

* General Sector Average

Performance Comparison

TW:6492 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6492	Senhwa Biosciences Inc	30.10	-11.52	-27.68%
TW:1786	SciVision Biotech Inc.	52.00	-20.06	-27.83%
TW:6838	Formosa Pharmaceuticals, Inc.	20.35	-7.30	-26.40%
TW:6875	Pharmosa Biopharm Inc.	25.25	-24.25	-48.99%
TW:6885	BRIM Biotechnology, Inc.	29.50	-0.05	-0.17%
TW:7427	Great Novel Therapeutics Biotech & Medicals Corp.	59.00	18.63	46.16%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Senhwa Biosciences Inc AI Stock Analysis